{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:49Z","timestamp":1790743729497,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7871","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2021,8,12]]},"DOI":"10.1038\/s41586-021-03693-y","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T12:04:25Z","timestamp":1623326665000},"page":"273-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":328,"title":["BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants"],"prefix":"10.1038","volume":"596","author":[{"given":"Jianying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-7038","authenticated-orcid":false,"given":"Hongjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-8556","authenticated-orcid":false,"given":"Scott C.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2273","authenticated-orcid":false,"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-016X","authenticated-orcid":false,"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-6360","authenticated-orcid":false,"given":"Philip R.","family":"Dormitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"3693_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","volume":"592","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116\u2013121 (2021).","journal-title":"Nature"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3693_CR5","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2106083 (2021).","DOI":"10.1056\/NEJMc2106083"},{"key":"3693_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003565","volume":"9","author":"EC Smith","year":"2013","unstructured":"Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565 (2013).","journal-title":"PLoS Pathog."},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e19 (2020).","journal-title":"Cell"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","volume":"183","author":"L Yurkovetskiy","year":"2020","unstructured":"Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739\u2013751.e8 (2020).","journal-title":"Cell"},{"key":"3693_CR10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464\u20131468 (2020).","journal-title":"Science"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-021-03361-1","volume":"592","author":"B Zhou","year":"2021","unstructured":"Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122\u2013127 (2021).","journal-title":"Nature"},{"key":"3693_CR12","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127-20 (2020).","journal-title":"J. Virol."},{"key":"3693_CR13","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Preprint at https:\/\/doi.org\/10.1101\/2021.03.08.434499 (2021).","DOI":"10.1101\/2021.03.08.434499"},{"key":"3693_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20789-7","volume":"12","author":"Z Ku","year":"2021","unstructured":"Ku, Z. et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat. Commun. 12, 469 (2021).","journal-title":"Nat. Commun."},{"key":"3693_CR15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"3693_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00313-8","volume":"6","author":"J Zou","year":"2021","unstructured":"Zou, J. et al. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines 6, 44 (2021).","journal-title":"NPJ Vaccines"},{"key":"3693_CR18","unstructured":"World Health Organization Coronavirus Disease (COVID-19): Weekly Epidemiological Update (11 May 2021) https:\/\/reliefweb.int\/report\/world\/coronavirus-disease-covid-19-weekly-epidemiological-update-11-may-2021 (OCHA, 2021)."},{"key":"3693_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"3693_CR20","doi-asserted-by":"publisher","unstructured":"Tada, T. et al. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies. Preprint at https:\/\/doi.org\/10.1101\/2021.05.14.444076 (2021).","DOI":"10.1101\/2021.05.14.444076"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3693_CR22","doi-asserted-by":"publisher","unstructured":"Edara, V. V. et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. Preprint at https:\/\/doi.org\/10.1101\/2021.05.09.443299 (2021).","DOI":"10.1101\/2021.05.09.443299"},{"key":"3693_CR23","doi-asserted-by":"publisher","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Preprint at https:\/\/doi.org\/10.1101\/2021.05.04.442663 (2021).","DOI":"10.1101\/2021.05.04.442663"},{"key":"3693_CR24","doi-asserted-by":"publisher","unstructured":"Tchesnokova, V. et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. Preprint at https:\/\/doi.org\/10.1101\/2021.02.22.432189 (2021).","DOI":"10.1101\/2021.02.22.432189"},{"key":"3693_CR25","doi-asserted-by":"publisher","unstructured":".Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2104974 (2021).","DOI":"10.1056\/NEJMc2104974"},{"key":"3693_CR26","doi-asserted-by":"publisher","unstructured":"Bernal, J. L. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. Preprint at https:\/\/doi.org\/10.1101\/2021.05.22.21257658 (2021).","DOI":"10.1101\/2021.05.22.21257658"},{"key":"3693_CR27","doi-asserted-by":"publisher","unstructured":"Tauzin, A. et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. Preprint at https:\/\/doi.org\/10.1101\/2021.03.18.435972 (2021).","DOI":"10.1101\/2021.03.18.435972"},{"key":"3693_CR28","doi-asserted-by":"publisher","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature https:\/\/doi.org\/10.1038\/s41586-021-03653-6 (2021).","DOI":"10.1038\/s41586-021-03653-6"},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41596-021-00491-8","volume":"16","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protocols 16, 1761\u20131784 (2021).","journal-title":"Nat. Protocols"},{"key":"3693_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03693-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T11:30:24Z","timestamp":1672399824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03693-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":30,"journal-issue":{"issue":"7871","published-print":{"date-parts":[[2021,8,12]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1038\/s41586-021-03693-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-540721\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.X. and P.-Y.S. have filed a patent on the reverse genetic system of SARS-CoV-2. K.A.S., H.C., M.C., D.C., K.U.J., and P.R.D. are employees of Pfizer and may hold stock options. A.M. and U.S. are employees of BioNTech and may hold stock options. Y.L., H.X., J.Z., X.X. and P.-Y.S. received compensation from Pfizer to perform the project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}